Shattuck Labs, Inc.
AUSTIN, TX · Founded 2016 · CIK 0001680367 · Biotech · Public
DR3-targeting monoclonal antibodies for inflammatory and immune-mediated diseases
shattucklabs.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $164M
- 5 Form D · Jun 2020
- 76 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 12 granted · 28 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,725,826 | |
| Private capital raised | Form D · SEC | $7,000,000 | |
| Private capital raised | Form D · SEC | $46,618,910 | |
| Private capital raised | Form D · SEC | $25,379,957 | |
| Private capital raised | Form D · SEC | $83,000,009 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3378 | SYGNAMAP, INC. | — | — |
| 3379 | Polyrizon Ltd. | — | $7.5M |
| 3380 | BlossomHill Therapeutics | — | $246M |
| 3381 | Shattuck Labs, Inc. | — | $164M |
| 3382 | Colossal Biosciences | — | $150M |
| 3383 | PepGen Inc. | — | $127M |
| 3384 | MouSensor, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Tyler BrousDirector
- Charles DorranceDirector
- Neil GibsonDirector
- Charles GolumbeskiDirector
- George GolumbeskiDirector
- Josiah HornblowerDirector · Executive Officer
- Chris HurffDirector
- Mike LeeDirector
- G. LoewenbaumDirector
- Walter LoewenbaumDirector
- David LoweDirector · Executive Officer
- Taylor SchreiberDirector · Executive Officer
- Victor StoneDirector
Patents
- Antibodies That Bind TNFRSF25application
- Fusion Proteins For The Treatment Of Nonalcoholic Steatohepatitisapplication
- Modified Mrna Therapeuticsapplication
- Chimeric Proteins For Treating Cutaneous Inflammationapplication
- Fusion Proteins For The Treatment Of Cardiometabolic Diseasesgranted
- Chimeric Proteins In Autoimmunityapplication
- Antibodies That Bind TNFRSF25granted
- Clinical Dosing Of SIRP1A Chimeric Proteinapplication
- Methods Of Contaminant Removal From Protein Isolatesapplication
- Antibodies That Bind TNFRSF25granted
- Fusion Proteins For The Treatment Of Cardiometabolic Diseasesapplication
- Fusion Proteins For The Treatment Of Cardiometabolic Diseasesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.